DigestRedComo funciona
Red
/
Empresas
Im
No verificado

ImmunityBio, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

59 Comunicados de prensa

Ver todos los comunicados de prensa
13/03/2026
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
26/02/2026
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
23/02/2026
Eventos
Biotecnología
Salud
Oncología
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
23/02/2026
Mercado de valores
Ciencia
Sanidad
Farmacéutica
Oncología
Material médico sanitario
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Biotecnología
Higiene alimentaria
Salud
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
20/02/2026
Mercado laboral
Industria
Ciencia
Sanidad
Farmacéutica
Oncología
Material médico sanitario
Medicina - Varios
Biotecnología
Higiene alimentaria
Salud
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
19/02/2026
Industria
Biotecnología
Sanidad
Salud
Farmacéutica
Oncología
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
18/02/2026
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Oncología
Ciencia
Material médico sanitario
Medicina - Varios
Industria
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
17/02/2026
Eventos
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Oncología
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
23/01/2026
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
16/01/2026
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0